TriangleCamizestrant (NCT07427394)
Camizestrant trial for Advanced Breast Cancer (NCT07427394). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with advanced ER-positive, HER2-negative breast cancer that progressed after a CDK4/6 inhibitor with endocrine therapy. Two or more prior advanced-disease CDK4/6 treatment lines are excluded.
The idea: test oral camizestrant with atirmociclib, after an initial atirmociclib dose alone. Camizestrant degrades estrogen receptors; atirmociclib blocks CDK4, a cell-division regulator. Researchers assess safety, drug levels and early tumor activity. Premenopausal participants also need ongoing ovarian suppression with a GnRH agonist, started at least four weeks earlier.
This phase 2 study plans 24 patients. AstraZeneca sponsors three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.